hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06275685, orgStudyIdInfo id: CIP-0001510, briefTitle: Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking, acronym: Foresight, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Empatica, Inc., class: INDUSTRY, descriptionModule briefSummary: The goal of this interventional study is to develop a personalized seizure risk forecast tool in people with epilepsy.The main questions it aims to answer are:* can we develop a future seizure probabilities tool that is more accurate than chance based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables.* does this tool improve the lives of people with epilepsy?Researchers will compare a group that does not have access to the forecast tool to a group that does and see if it is accurate and if people with it report that it improved their quality of life., conditionsModule conditions: Epilepsy; Seizure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 3000, type: ESTIMATED, armsInterventionsModule interventions name: SeizureWise algorithm, interventions name: Multi-day Visualizations, outcomesModule primaryOutcomes measure: Sensitivity of SeizureWise, secondaryOutcomes measure: Change in QoL and psychological health indicators using the Quality of life in epilepsy (QOLIE-10-P), secondaryOutcomes measure: Qualitative assessment of multi-day visualizations, secondaryOutcomes measure: Stress level with visualizations using the brief epilepsy anxiety survey instrument (brEASI-8), secondaryOutcomes measure: Modifiable behavior change, secondaryOutcomes measure: Accuracy of SeizureWise low-likelihood forecast, secondaryOutcomes measure: Accuracy of SeizureWise high-likelihood forecast, eligibilityModule sex: ALL, minimumAge: 6 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06275659, orgStudyIdInfo id: CT-100-D-003, briefTitle: An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-12-04, primaryCompletionDateStruct date: 2024-02-23, completionDateStruct date: 2024-03-18, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Click Therapeutics, Inc., class: INDUSTRY, descriptionModule briefSummary: CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics. One class of CT-100 components are Digital Neuro-activation and Modulation (DiNaMo TM) components.DiNaMo components target key neural systems (including but not limited to systems related to sensory-, perceptual-, affective-, pain-, attention-, cognitive control, social- and self- processing) to optimally improve a participant's health., conditionsModule conditions: Psoriasis, conditions: Atopic Dermatitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 120, type: ACTUAL, armsInterventionsModule interventions name: CT-100-004-A, interventions name: CT-100-004-B, outcomesModule primaryOutcomes measure: Change in Peak Pruritus Numerical Rating Scale, primaryOutcomes measure: Change in Dermatology Life Quality Index, primaryOutcomes measure: Change in Quality of Life symptoms, primaryOutcomes measure: Time in App, primaryOutcomes measure: Experience with Study App, primaryOutcomes measure: Improved global rating of change, secondaryOutcomes measure: Frequency of Adverse Events, secondaryOutcomes measure: Severity of Adverse Events, secondaryOutcomes measure: Frequency of Serious Adverse Events, secondaryOutcomes measure: Severity of Serious Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Click Therapeutics, city: New York, state: New York, zip: 10013, country: United States, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06275646, orgStudyIdInfo id: Adeel2, briefTitle: Comparison Of Outcome Of Different Layers in Hypospadias Surgery, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2022-12-31, completionDateStruct date: 2023-04-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Children Hospital and Institute of Child Health, Lahore, class: OTHER, descriptionModule briefSummary: To compare the outcome of applying autologous platelet-rich plasma membrane layer and dartos fascial flap versus only dartos fascial flap in mid and distal penile hypospadias surgery. A total of 220 patients fulfilling the selection criteria were admitted after taking informed consent. Cases were randomly divided into groups A and B using a random generator of the Excel program. In group A, dartos flap and PRP sheet layer were applied and in group B, only a preputial dartos fascial flap was applied, conditionsModule conditions: Hypospadias, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized control trial, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 220, type: ACTUAL, armsInterventionsModule interventions name: PRP layer, interventions name: dartos flap, outcomesModule primaryOutcomes measure: wound infectiom, primaryOutcomes measure: frequency of glans dehiscence, primaryOutcomes measure: frequency of meatal stenosis, eligibilityModule sex: MALE, minimumAge: 6 Months, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: The Children Hospital, city: Lahore, state: Punjab, zip: 42000, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, hasResults: False
protocolSection identificationModule nctId: NCT06275633, orgStudyIdInfo id: H-18055648, briefTitle: Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-03-19, primaryCompletionDateStruct date: 2021-12-03, completionDateStruct date: 2023-07-30, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: University Hospital Bispebjerg and Frederiksberg, class: OTHER, descriptionModule briefSummary: In this project, patients with Parkinson's Disease (PD) will be characterized by measuring cognitive and motor function and relation to effect of Levodopa.Participants will be patients with Parkinson's Disease and healthy controls. It will be investigated if there is a difference between patients with a good measured Levodopa response and with a poor measured response., conditionsModule conditions: Parkinson Disease, conditions: Medication, conditions: UPDRS, conditions: Motor Function, conditions: Cognitive Impairment, conditions: Depression, conditions: Impulsive, conditions: Levodopa, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This is a prospective patient with Parkinson's Disease cohort. After acute levodopa challenge test patients with Parkinson's Disease are divided due to measured levodopa response and their self-rated medicine effect., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, maskingDescription: There will be a blinded assessment of videos of participants with Parkinson's Disease ON and OFF medication, enrollmentInfo count: 68, type: ACTUAL, armsInterventionsModule interventions name: Levodopa, outcomesModule primaryOutcomes measure: Motor improvement, secondaryOutcomes measure: Cognitive function, otherOutcomes measure: Cognitive function, otherOutcomes measure: Depressive symptoms, otherOutcomes measure: Impulsivity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Bispebjerg and Frederiksberg, city: Copenhagen, state: Region Hovedstaden, zip: 2400, country: Denmark, geoPoint lat: 55.67594, lon: 12.56553, hasResults: False
protocolSection identificationModule nctId: NCT06275594, orgStudyIdInfo id: YUMC2023-12-017, briefTitle: Trial Evaluating the Efficacy of Remimazolam in Endobronchial Ultrasound Guided Transbronchial Needle Aspiration, acronym: REST, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Yeungnam University Hospital, class: OTHER, descriptionModule briefSummary: Study to evaluate the efficacy and safety of remimazolam in patients undergoing endobronchial ultrasound-guided transbronchial needle aspirationPrimary Outcome Evaluate and compare the success of the procedure in patients undergoing EBUS-TBNA (Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration) when administered with remimazolam in the experimental group, versus Real world midazolam (Control Group 1), and On label midazolam (Control Group 2).Secondary Outcome In patients undergoing EBUS-TBNA, compare the following aspects when administered with remimazolam in the experimental group versus Real world midazolam (Control Group 1) and On label midazolam (Control Group 2): Procedure start time, Time taken to achieve full alertness, Need for flumazenil administration, Total dose of fentanyl used, Scale of coughing/discomfort/convenience, Changes in vital signs, Complications related to the procedure., conditionsModule conditions: Midazolam, conditions: Remimazolam, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 330, type: ESTIMATED, armsInterventionsModule interventions name: Byfavo, interventions name: Midazolam, outcomesModule primaryOutcomes measure: Procedural success during EBUS-TBNA (composite outcome), secondaryOutcomes measure: Time to start of procedure after administration of the first dose of study medication, secondaryOutcomes measure: Time taken to achieve full alertness after the procedure, secondaryOutcomes measure: Requirement for flumazenil dosage during the procedure, secondaryOutcomes measure: Total fentanyl dose, secondaryOutcomes measure: Scale of coughing/discomfort/inconvenience, secondaryOutcomes measure: Changes in blood pressure, secondaryOutcomes measure: Changes of heart rate, secondaryOutcomes measure: Changes in respiration rate, secondaryOutcomes measure: Complications related to the procedure, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Yeungnam University Hospital, city: Daegu, state: Namgu, zip: 42415, country: Korea, Republic of, contacts name: June Hong Ahn, M.D. PhD, role: CONTACT, phone: 821028562008, email: fireajh@gmail.com, geoPoint lat: 35.87028, lon: 128.59111, hasResults: False
protocolSection identificationModule nctId: NCT06275568, orgStudyIdInfo id: HSC-SPH-23-0655, briefTitle: Accelerating Healthcare Engagement in Healthy Food Interventions - Food Rx in High Risk Pregnant Mothers With About Fresh and Texas Children's Health Plan, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-11-15, completionDateStruct date: 2024-11-15, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: The University of Texas Health Science Center, Houston, class: OTHER, descriptionModule briefSummary: The purpose of the study is to assess if the Fresh Connect food prescription (Fresh Connect Food Rx) program that provides consistent access to healthy fresh produce through purchases at the grocery store plus nutrition education impacts gestational weight gain, other pregnancy and birth outcomes, and food and nutrition security in low-income, ethnically diverse, at-risk women residing in Houston, Texas. Enrollment of participants will begin in pregnancy at the time of the first prenatal visit (as long as the first visit occurs before the end of the first trimester); each participant will be followed until 60 days post-partum (up to 11 months follow-up per participant)., conditionsModule conditions: Nutrition in High-Risk Pregnancy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 620, type: ESTIMATED, armsInterventionsModule interventions name: Usual Care Fresh Connect cardholder engagement, interventions name: Enhanced engagement communication, outcomesModule primaryOutcomes measure: Absolute gestational weight gain (GWG) in pounds, primaryOutcomes measure: Absolute gestational weight gain (GWG) in pounds, primaryOutcomes measure: Absolute gestational weight gain (GWG) in pounds, primaryOutcomes measure: Excess gestational weight gain (EGWG) in pounds, primaryOutcomes measure: Excess gestational weight gain (EGWG) in pounds, primaryOutcomes measure: Excess gestational weight gain (EGWG) in pounds, secondaryOutcomes measure: Number of participants diagnosed with pregnancy-induced hypertension, secondaryOutcomes measure: Number of participants diagnosed with gestational diabetes, secondaryOutcomes measure: Number of participants with pre-term birth (<37 weeks), secondaryOutcomes measure: Infant birth weight, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 44 Years, stdAges: ADULT, contactsLocationsModule locations facility: The University of Texas Health Science Center at Houston, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Shreela Sharma, PhD, role: CONTACT, phone: 713-500-9344, email: Shreela.V.Sharma@uth.tmc.edu, contacts name: Naomi Tice, MPH, role: CONTACT, phone: (713) 500-9000, email: Naomi.Tice@uth.tmc.edu, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06275555, orgStudyIdInfo id: 2023-101, briefTitle: Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Xiaotong Hou, class: OTHER, descriptionModule briefSummary: The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin., conditionsModule conditions: Extracorporeal Membrane Oxygenation Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 154, type: ESTIMATED, armsInterventionsModule interventions name: bivalirudin, interventions name: unfractionated heparin, outcomesModule primaryOutcomes measure: thrombotic complications, primaryOutcomes measure: bleeding complications, secondaryOutcomes measure: Hospitalization mortality, secondaryOutcomes measure: Loop replacement, secondaryOutcomes measure: Infusion volume of blood products, secondaryOutcomes measure: Acute renal failure, secondaryOutcomes measure: Heparin-induced thrombocytopenia, secondaryOutcomes measure: the time of reaching the target anticoagulant level for the first time, secondaryOutcomes measure: Percentage of time during ECMO within the target anticoagulant level, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Anzhen Hospital, city: Beijing, state: Beijing, zip: 100029, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06275529, orgStudyIdInfo id: 27.12.2023.685, briefTitle: Evaluation of Transforaminal Epidural Steroid Injection in Radicular Low Back Pain According to MSU Classification, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-06-15, completionDateStruct date: 2024-08-15, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Başakşehir Çam & Sakura City Hospital, class: OTHER_GOV, descriptionModule briefSummary: Low back pain is a common disease in all ages and it effects seriously quality of life. Medical treatment,interventional methods and surgery are the treatment options. Transforaminal epidural steroid injections (TFSI) is one of the interventional method for radiculopathy with low back pain. Michigan State University(MSU) classification is a MRI based disc herniation classification. It helps to classified disc herniation in types, places and sizes.The aim of this study to evaluate the pain and oswestry disability index in patients who have radiculopathy with low back pain, undergone TFSI according to MSU classification., conditionsModule conditions: Radiculopathy Lumbar, conditions: Low Back Pain, conditions: Disc Herniation, conditions: Injections, Epidural, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 160, type: ESTIMATED, armsInterventionsModule interventions name: Transforaminal Epidural Steroid Injection, outcomesModule primaryOutcomes measure: Change of the pain severity score, primaryOutcomes measure: Change of the disability score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06275516, orgStudyIdInfo id: 2024-208, briefTitle: Safety and Efficacy of Multisensory Stimulation Virtual Reality for Stroke Patients., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2024-06-20, completionDateStruct date: 2024-09-20, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: First Affiliated Hospital of Chongqing Medical University, class: OTHER, descriptionModule briefSummary: This was a single-blind randomized controlled trial of multisensory stimulation virtual reality to improve motor and cognitive dysfunction in stroke patients., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: multi-sensory stimulation immersive VR+ treadmill training, interventions name: treadmill training, outcomesModule primaryOutcomes measure: Fugl-Meyer scale, primaryOutcomes measure: Berg balance scale, primaryOutcomes measure: three-dimensional gait detection, primaryOutcomes measure: Fall incidents, primaryOutcomes measure: Dizzy incidents, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06275464, orgStudyIdInfo id: BT-600-101, briefTitle: BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-11, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Biora Therapeutics, Inc., class: INDUSTRY, descriptionModule briefSummary: This is a randomized, double-blind, placebo-controlled Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BT-600 when administered in single and multiple ascending doses to healthy participants. The study will enroll up to 48 participants, with participation lasting 2-3 weeks in addition to up to 28 days (about 4 weeks) for screening.The purposes of this study are to learn about the safety and tolerability of single and multiple rising oral doses of BT-600, assess the blood and tissue levels of tofacitinib released from BT-600, and assess the body's effects to the study drug following oral doses of BT-600 in blood and tissue in healthy adult participants.BT-600 is a swallowable drug/device combination product designed to deliver a liquid formulation of tofacitinib to the colon and dispense the study drug throughout the colon. BT-600 consists of two components, the drug part containing a reservoir, which will be filled with liquid tofacitinib, and the drive part. The drive part contains the hardware and software that identifies the colon region and then dispenses the drug to the specific region. The device which contains the drug is referred to as the NaviCap™ device. The NaviCap device is approximately the size of a fish oil pill, is made of plastic material known to be safe for ingestion and has rounded ends for ease of swallowing. Liquid tofacitinib in the reservoir is automatically released when the BT-600 localization technology determines that it has reached the colon. BT-600 passes through the colon and the NaviCap device is excreted via a bowel movement., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: BT-600, interventions name: BT-600 Placebo, outcomesModule primaryOutcomes measure: Adverse Events, secondaryOutcomes measure: Pharmacokinetic (PK) Assessments, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Celerion, status: RECRUITING, city: Lincoln, state: Nebraska, zip: 68502, country: United States, geoPoint lat: 40.8, lon: -96.66696, hasResults: False